Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,653 across all filing types
Latest filing 2023-05-10 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
中信证券股份有限公司关于贝达药业股份有限公司2022年度持续督导培训情况的报告
Regulatory Filings Classification · 95% confidence The document is a report from CITIC Securities regarding the 2022 continuous supervision training conducted for Betta Pharmaceuticals Co., Ltd. It details the training session's participants, content, and outcomes. The document references regulatory guidelines from the Shenzhen Stock Exchange and focuses on compliance and training rather than financial results or corporate governance changes. It is not an annual report, earnings release, or management report. It is a specific report related to regulatory compliance and training activities, which fits best under Regulatory Filings (RNS) as it does not match other more specific categories.
2023-05-10 Chinese
中信证券股份有限公司关于贝达药业股份有限公司向特定对象发行股票持续督导保荐总结报告书
Capital/Financing Update Classification · 95% confidence The document is titled as a "持续督导保荐总结报告书" (Continuous Supervision Sponsorship Summary Report) by CITIC Securities regarding a specific share issuance by Betta Pharmaceuticals. It details the continuous supervision work done by the sponsor during the period from the stock issuance date (December 17, 2020) to December 31, 2022. The content includes descriptions of due diligence, supervision of governance, use of raised funds, and compliance with regulatory requirements. It is not a full annual or interim financial report, nor an earnings release or a proxy statement. It is a detailed report related to the sponsorship and supervision of a capital raising event (private placement of shares). This fits the category of Capital/Financing Update (CAP), as it provides a comprehensive update on the financing activity and the sponsor's oversight work. The document length is 3159 characters, which is sufficient for a detailed report but not a full annual report. Therefore, the classification is CAP with high confidence.
2023-05-10 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2022年度持续督导工作定期现场检查报告
Audit Report / Information Classification · 95% confidence The document is titled as a "2022年度持续督导工作定期现场检查报告" which translates to "2022 Annual Continuous Supervision Work Regular On-site Inspection Report" by CITIC Securities for Betta Pharmaceuticals. It details the on-site inspection of governance, internal control, information disclosure, use of raised funds, performance, and other compliance matters for the year 2022. The content is a detailed inspection report rather than a general annual report or financial statement. It is not an announcement or a brief summary but a substantive report on regulatory supervision and compliance. This fits the definition of an Audit Report / Information (AR) as it relates to audit and regulatory inspection results, internal controls, and compliance checks, excluding full annual financial statements. The document length is 3567 characters, which is substantive but not a full annual report. Therefore, the classification is AR with high confidence. FY 2022
2023-05-10 Chinese
关于股东股份质押变动的公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement regarding changes in shareholder stock pledges for a company (贝达药业股份有限公司). It details the number of shares pledged and released by a major shareholder, the proportion of shares pledged relative to total holdings and company stock, and the implications of these pledges on company control and operations. There are no financial statements, earnings data, or management discussion of financial results. The document is a regulatory disclosure about share pledge changes, which fits the category of Major Shareholding Notification (MRQ) as it involves significant share ownership and pledge status changes by a controlling shareholder. The document length is 2462 characters, which is typical for such announcements and not a full report or earnings release. Therefore, the appropriate classification is MRQ with high confidence.
2023-05-10 Chinese
中信证券股份有限公司关于贝达药业股份有限公司2022年度募集资金存放与使用情况的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed report from CITIC Securities regarding the 2022 annual verification of the storage and use of raised funds by Betta Pharmaceuticals Co., Ltd. It includes extensive financial data on fundraising amounts, usage, balances, investment projects, changes in project funding, and compliance with regulatory requirements. It also contains auditor opinions and verification reports related to the use of raised funds. The document is lengthy (15,000 characters) and contains substantive financial data and analysis about the fundraising and its use during the fiscal year 2022. This matches the characteristics of an Audit Report / Information (AR), which includes standalone audit reports and applied accounting principles related to specific financial aspects, here focusing on fundraising and its management. It is not a full Annual Report (10-K) as it focuses specifically on fundraising usage and verification, nor is it a simple announcement or certification. Therefore, the appropriate classification is AR with high confidence. FY 2022
2023-05-10 Chinese
中信证券股份有限公司关于贝达药业股份有限公司使用暂时闲置募集资金进行现金管理的核查意见
Audit Report / Information Classification · 95% confidence The document is a detailed opinion and verification report from CITIC Securities regarding the use of temporarily idle raised funds by Betta Pharmaceuticals for cash management. It references regulatory compliance, board and supervisory approvals, independent director opinions, and the role of the sponsor institution. The document includes specifics about the raised funds, investment purpose, risk control measures, and approvals but does not contain actual financial statements or quarterly/yearly financial results. It is a verification or audit-type report related to the use of funds, not a full annual or interim report, earnings release, or other financial report. The document length is 4152 characters, which is relatively short but contains substantive content. It is not a simple announcement or certification but a formal audit/verification opinion on a specific financial management matter. Therefore, it fits best under Audit Report / Information (AR). FY 2023
2023-05-10 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.